Lucid Diagnostics Provides Business Update and Reports Second Quarter 2025 Financial Results
Processed 2,756 EsoGuard® tests and recognized 2Q25 revenue of $1.2 million, ending quarter with over $30 million in proforma cash and extending runway well past upcoming reimbursement milestones M...
Are there any forward‑looking guidance updates or non‑GAAP metrics that could reshape expectations for Lucid’s 2025‑2026 financial outlook?
What macro or sector trends (e.g., healthcare policy, diagnostic adoption) could amplify or dampen the market reaction to this update?
How might the Q2 results influence analyst coverage, earnings revisions, and institutional positioning in LCDI?
28 days ago